dvm360 podcast spotlights the clinical and family journey of MMVD: full analysis
Version 2
A new Vet Blast Podcast episode from dvm360 puts a familiar cardiology problem into a case-based format for general practitioners: the long arc of canine myxomatous mitral valve disease. Published March 19, 2026, the episode follows “Vinnie,” a 7-year-old Chihuahua, as cardiologist Whit Church, DVM, DACVIM, and host Adam Christman, DVM, MBA, discuss how MMVD is first recognized, how it progresses, and how veterinarians can help families navigate the disease over time. The episode was sponsored by Boehringer Ingelheim, a major player in the MMVD treatment space. (dvm360.com)
The clinical backdrop is well established. MMVD is the most common chronic valvular heart disease in dogs and is especially common in older, small-breed patients. A heart murmur is often the first clue in general practice, long before overt signs of congestive heart failure appear. In Vinnie’s case, Church described an asymptomatic dog referred after a left-sided murmur was detected, with echocardiography confirming degenerative mitral valve changes but no heart enlargement at that stage, a scenario consistent with early preclinical disease. (animalhealth.boehringer-ingelheim.com)
That distinction matters because staging changes management. The 2019 ACVIM consensus guidelines define Stage B2 MMVD as asymptomatic disease with more advanced mitral regurgitation and cardiomegaly, using criteria that include murmur intensity of at least 3/6, left atrial enlargement, increased normalized left ventricular internal diameter, and radiographic evidence of heart enlargement. In dogs meeting those criteria, the guidelines recommend pimobendan to delay the onset of heart failure. (animalhealth.boehringer-ingelheim.com)
The evidence base for that recommendation comes largely from the EPIC trial, a prospective, randomized, blinded, placebo-controlled study in 360 client-owned dogs with preclinical MMVD and cardiomegaly. The study found that pimobendan significantly prolonged the time to the composite endpoint of congestive heart failure, cardiac-related death, or euthanasia. That trial helped shift MMVD management toward earlier intervention in Stage B2 rather than waiting for clinical heart failure to develop. (academic.oup.com)
Although the dvm360 piece is educational rather than a new research report, its framing reflects a broader industry emphasis on earlier recognition and better continuity of care. Church’s discussion of heritability, age-related progression, and the variable pace of disease mirrors what cardiology services and consensus documents have highlighted for years: many dogs live in a long preclinical phase, but once enlargement develops, monitoring cadence, treatment planning, and pet parent communication become more consequential. North Carolina State University’s cardiology service similarly notes that Stage B1 cases are typically monitored, while Stage B2 dogs benefit from medication to delay CHF onset. (dvm360.com)
Why it matters: For veterinary teams, the practical takeaway is less about novelty than execution. MMVD is common enough that early murmurs will usually be found in primary care first, not specialty practice. That means auscultation quality, decisions about when to recommend echocardiography or thoracic imaging, and confidence in explaining ACVIM staging can directly affect outcomes and pet parent expectations. It also underscores that MMVD care is not just pharmacologic. The podcast’s emphasis on the “family journey” points to a real clinical need: helping pet parents understand what monitoring means, when asymptomatic disease becomes actionable, and how to prepare for eventual CHF or end-of-life decisions without losing trust along the way. (dvm360.com)
There’s also a commercial context worth noting. Because the episode was sponsored by Boehringer Ingelheim, clinicians may want to separate the educational value from the promotional environment and anchor recommendations in guideline-based care and primary literature. In this case, the core messages in the episode, including early recognition, staging, and treatment at Stage B2, align with ACVIM guidance and the EPIC trial evidence base. (dvm360.com)
What to watch: The next development to monitor is not likely a sudden change in MMVD staging, but how consistently primary care teams apply existing guidance, how referral pathways evolve, and whether newer real-world data further refine which preclinical dogs benefit most from earlier intervention and closer follow-up. (journals.plos.org)